A randomized phase III study to evaluate the effects of Oxpentifyllene as an add on therapy for boys with duchenne muscular dystrophy in improving muscle strength and function.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000078651

Enrollment

Registered

2005-08-05

Start date

2005-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Oxpentifylline is being trialled as an add on drug to steroids - at present the only known med to positively influence DMD. It is thought that it may reduce some of the secondary problems in muscles such as fibrosis and inflammation.

Interventions

12-month trial of steroids plus Oxpentifylline as an add on treatment

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

7 Years to 18 Years

Healthy volunteers

Inclusion criteria

Duchenne muscular dystrophy, ambulant, stable dose of steroids for 12 months.

Exclusion criteria

No exclusion criteria

Outcome results